ACP
NBIX icon

Acuta Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Acuta Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-31,500
Closed -$704K – 60
2014
Q4 		$704K Buy
+31,500
New +$597K 0.48% 50

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Acuta Capital Partners's NBIX Position: Q3 2016 in Review

Acuta Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 42,000 shares — an estimated $1.91M sold.

Acuta Capital Partners first reported a position in NBIX in Q4 2015 and held it in 2 quarters. The position peaked at $3.17M in Q4 2015. 245 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • Acuta Capital Partners reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 42,000 Neurocrine Biosciences shares in Q3 2016, an estimated $1.91M.
  • Acuta Capital Partners first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 2 quarters.
  • Acuta Capital Partners's Neurocrine Biosciences position peaked at $3.17M in Q4 2015.
  • 245 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.